BRISTOL MYERS SQUIBB CO (BMY)
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
📈 **POSITIVE** • Medium confidence analysis (74%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business